Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

XLV vs PHSYX overlap: 67% of top holdings shared

Bottom line

How much do XLV and PHSYX overlap?

67% of their top holdings overlap by weight. 16 securities appear in both funds' top 25, making up 70.0% of XLV's assets and 65.4% of PHSYX's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

XLVPHSYX
Weight overlap (top 25)67%
Shared holdings16
Weight in shared holdings70.0%65.4%
Total positions65115
Expense ratio0.08%0.79%
Holdings as ofJun 30, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)

Holdings XLV and PHSYX have in common

Holding% of XLV% of PHSYXOverlap
Eli Lilly & Co16.51%13.15%13.15%
Johnson & Johnson10.64%8.46%8.46%
AbbVie Inc7.74%6.05%6.05%
UnitedHealth Group Inc6.57%6.93%6.57%
Merck & Co Inc5.52%4.88%4.88%
Amgen Inc3.40%1.11%1.11%
Thermo Fisher Scientific Inc3.24%4.50%3.24%
Gilead Sciences Inc2.73%2.63%2.63%
Intuitive Surgical Inc2.45%4.04%2.45%
CVS Health Corp2.30%2.74%2.30%
Vertex Pharmaceuticals Inc2.19%1.97%1.97%
Bristol-Myers Squibb Co2.05%1.75%1.75%
McKesson Corp1.58%2.14%1.58%
Boston Scientific Corp1.10%1.80%1.10%
HCA Healthcare Inc1.05%1.18%1.05%
Cardinal Health Inc0.97%2.12%0.97%

Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in XLV

  1. Abbott Laboratories — 2.75%
  2. Pfizer Inc — 2.39%
  3. Danaher Corp — 2.09%
  4. Stryker Corp — 1.89%
  5. Medtronic PLC — 1.75%
  6. Elevance Health Inc — 1.46%
  7. Cigna Group/The — 1.27%
  8. Regeneron Pharmaceuticals Inc — 1.08%
  9. Cencora Inc — 0.96%

Only in PHSYX

  1. Novartis AG — 5.13%
  2. AstraZeneca plc — 4.67%
  3. Sanofi SA — 3.23%
  4. Edwards Lifesciences Corp. — 2.80%
  5. Roche Holding AG — 2.79%
  6. Novo Nordisk A/S — 1.90%
  7. Dexcom, Inc. — 1.64%
  8. Hoya Corp. — 1.52%
  9. Putnam Short Term Investment Fund — 1.35%

Asset mix

Asset typeXLVPHSYX
Stocks99.7%98.2%
Other—1.4%
Cash & short-term funds0.3%0.6%

Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)

Country mix

CountryXLVPHSYX
US97.9%76.2%
CH—7.9%
GB—6.4%
FR—3.2%
DK—2.4%
JP—2.4%
IE2.1%—
NL—1.2%

Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)

Check another pair

FAQ

How much do XLV and PHSYX overlap?
About 67% by weight. 16 securities appear in both funds' top 25 holdings; they make up 70.0% of XLV's assets and 65.4% of PHSYX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do XLV and PHSYX have in common?
The largest shared holdings are Eli Lilly & Co, Johnson & Johnson, UnitedHealth Group Inc, AbbVie Inc, Merck & Co Inc.
Should I own both XLV and PHSYX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, XLV or PHSYX?
PHSYX is broader, with 115 positions versus 65 for XLV. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.